Explore the innovative subcutaneous delivery of isatuximab for multiple myeloma, enhancing patient experience and treatment ...

It's an injection given under the skin (subcutaneous injection). Your healthcare provider will decide if you or your caregiver can inject DUPIXENT.

Patients in the omalizumab group had a mean (SD) age of 74.8 (10.1) years, 50.0% were women, and the mean disease duration was 29.3 months. Dupilumab was administered in a 600 mg loading dose, ...

Find out how Xolair treats asthma, hives, chronic sinusitis, allergies, nasal polyps, and how long it takes to start working.

The Food and Drug Administration (FDA) has approved Omlyclo ® (omalizumab-igec), the first interchangeable biosimilar to Xolair ® (omalizumab). Omlyclo, formerly known as CT-P39, is an ...

The Food and Drug Administration (FDA) has approved Omlyclo ® (omalizumab-igec), the first interchangeable biosimilar to Xolair ® (omalizumab). Omlyclo, formerly known as CT-P39, is an ...

During the first period, study participants (N=619) were randomly assigned to receive omalizumab-igec 300mg, Xolair 300mg, omalizumab-igec 150mg, or Xolair 150mg for 12 weeks.

The approval is for 2 dosage forms: a 75 mg/0.5 mL injection and a 150 mg/mL injection, both to be administered in single-dose prefilled syringes for subcutaneous use—mirroring the respective Xolair ...

“Monoclonal antibodies are typically administered into the subcutaneous tissue via self-injection with a prefilled syringe or auto-injector,” says Sammon. Injections may be given once every 2 ...

XOLAIR is given in 1 or more injections under the skin (subcutaneous), 1 time every 4 weeks. In people with chronic hives, a blood test is not necessary to determine the dose or dosing frequency.